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Gland tumoursBackground: Treatment of local relapse in adenoid cystic carcinoma (ACC) following prior radiation
remains a challenge: without the possibility of surgical salvage patients face the choice between
palliative chemotherapy and re-irradiation. Chemotherapy yields response rates around 30% and applica-
tion of tumouricidal doses is difﬁcult due to proximity of critical structures. Carbon ion therapy (C12) is a
promising method to minimize side-effects and maximize re-treatment dose in this indication. We
describe our initial results for re-irradiation in heavily pre-treated ACC patients.
Methods: Patients treated with carbon ion therapy between 04/2010 and 05/2013 (N = 52 pts, median
age: 54 a) were retrospectively evaluated regarding toxicity (NCI CTC v.4), tumour response (RECIST)
and control rates. 48 pts (92.3%) received carbon ions only, 4 pts received IMRT plus C12.
Results: 4 pts were treated following R1-resection, 43 pts for inoperable local relapse. Most common
tumour sites were paranasal sinus (36.5%), parotid (19.2%), and base of skull (17.3%). Pts received a
median dose of 51 GyE C12/63 Gy BED and cumulative dose of 128 Gy BED [67–182 Gy] after a median
RT-interval of 61 months. Median target volume was 93 ml [9–618 ml]. No higher-grade (>II) acute
reactions were observed, 7 pts showed blood–brain-barrier changes (I/II: 8 pts; III: 2 pts), 1 pt corneal
ulceration, xerophthalmia 7 pts, IV bleeding 1 pt, tissue necrosis 2 pts, otherwise no signiﬁcant late reac-
tions. Objective response rate (CR/PR) was 56.6%. With a median follow-up of 14 months [1–39 months]
local control and distant control at 1a are 70.3% and 72.6% respectively. Of the 18 pts with local relapse,
13 pts have recurred in-ﬁeld, 1 pt at the ﬁeld edge, 3 pts out of ﬁeld, and one in the dose gradient.
Conclusion: Despite high applied doses, C12 re-irradiation shows moderate side-effects, response rates
even in these heavily pre-treated patients are encouraging and present a good alternative to palliative
chemotherapy. Though most local recurrences occur within the high-dose area, further dose escalation
should be viewed with caution.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 114 (2015) 182–188
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Local relapse in head and neck cancer is a very difﬁcult thera-
peutic situation. Chemotherapy rarely produces durable tumour
control; therefore surgery as a potentially curative treatment
option is the mainstay of salvage local therapy. For adenoid cystic
carcinoma, the situation becomes even more complex: skull baseinvasion and perineural spread often prevent complete resections
in the primary situation. Anatomical sites and relative radioresis-
tance of the disease mandate initial high radiation doses for
tumour control. In case of local relapse, treatment options are
limited. First treatment of choice is salvage surgery. If this is not
possible, patients’ options are limited: even highly aggressive che-
motherapy regimens for adenoid cystic carcinoma achieve only
objective response rates up to 30% [1], new agents such as EGFR-
or tyrosine-kinase inhibitors mostly stabilize disease for some time
[2–5]. Only one tyrosine kinase inhibitor has been shown to pro-
duce objective responses [6].
Re-irradiation has rarely been used in the past for fear of con-
siderable early and late toxicity; in addition, recurrent tumours
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clone [7]. Neutron and charged particle therapy produced encour-
aging local control rates albeit at considerable side-effects [8,9].
There is emerging evidence that re-irradiation can lead to long-
term local control in a selected subset of patients, [10–13] but local
control remains strongly dependent on re-irradiation dose
[11,13,14]. With the advent of modern radiotherapy techniques
such as stereotactic radiotherapy and IMRT, proportion of severe
treatment-related side-effects can be reduced [13,15–17] and
modern techniques for re-irradiation are increasingly offered to
patients with locally recurrent head and neck cancer. While sub-
stantial data including prospective phase I and II trials have been
reported for squamous cell head and neck cancer (SCCHN), there
are little data on retreatment of malignant salivary gland tumours.
Application of tumouricidal doses remains a challenge though due
to the proximity of critical structures in the head and neck.
Charged particle therapy in active beam application produces very
sharp dose gradients [18] and hence may improve outcome in this
desperate situation. We present our experience on re-irradiation of
adenoid cystic carcinoma of the head and neck with scanned car-
bon ion beams.Table 1
Patient characteristics and radiotherapy.
Patient characteristics
Pts %Methods
Patients
Treatment decision in all patients was based on interdisciplin-
ary consensus. Treatment-related toxicity was prospectively
collected, patient data were retrospectively analysed.Re-treatment site
Paranasal sinus 19 36.5
Base of skull/intracranial 11 21.2
Parotid 10 19.2
Submandibular gland 3 5.8
Nasopharynx 2 3.8
Pterygopalatine fossa 2 3.8
Orbit 2 3.8
Lacrimal gland 1 1.9
Auditory canal 1 1.9
Jaw angle 1 1.9
Re-treatment stage
T2 2 3.8
T3 10 19.2
T4 40 76.9
T4a 6 11.5
T4b 34 65.4
N1 1 1.9
N2a 1 1.9
N2b 3 5.8
N2c 1 1.9
M1 15 28.8
Prior surgery 7 13.5
Macroscopic tumour at re-RT 45 86.5
Radiotherapy
IMRT + C12-boost 4 7.7
C12 only 48 92.3
Median (Gy/GyE) Range (Gy/GyE)
Prior radiotherapy
Nominal dose 66 20–115
BED 66 20–133
Re-irradiation
Nominal dose 51 36–74
BED 63 45–82Radiotherapy
Patients were immobilized using individual ﬁxation devices
(scotch cast or thermoplastic head masks). As a standard, treat-
ment planning was carried out on 3 mm CT and contrast-enhanced
MRI scans for 3D image correlation.
Carbon ion therapy was carried out at the Heidelberg Ion Beam
Therapy Centre (HIT) in active beam application (raster-scanning
method [18]) in 3 GyE per fraction (exception: 1 patient received
3.5 Gy/fraction) and 5–6 fractions per week under daily image
guidance with orthogonal X-rays and position correction in six
degrees of freedom [19].
Re-irradiation target volume included only the visible local
relapse with a small safety margin (ca. 2 mm), no elective nodal
irradiation was carried out. There were 4 exceptions in this cohort
receiving combination treatment with IMRT and carbon ion boost.
These patient’s prior radiotherapy interval was either very long or
the prior radiotherapy dose was negligible in the area of relapse. In
these cases, C12 volume included the visible tumour plus small
safety margin, the IMRT volume included visible tumour, area at
risk of microscopic spread and locoregional nodal levels.
In all cases, cumulative dose to the brain stem and spinal cord
was kept below 60 Gy and 50 Gy respectively assuming around
50% recovery of the CNS [20]. In the cases where optic nerves were
involved in the tumour process, high probability of loss of vision
was discussed with the patients prior to treatment start. Dose pre-
scription was highly individual in each patient’s case taking into
account time to prior radiotherapy as well as prior radiotherapy
dose.Cumulative life-time dose
BED 128 67–182
Interval between RT courses 61 mo 9–620 mo
Treatment volume
CTV (C12) 93 ml 6–618 ml
CTV (IMRT); 4 pts only! 334 ml 211–344 mlFollow-up
Patients received regular follow-ups including MRI scans and
clinical exams 6–8 weeks post completion of radiotherapy, 3, 6,
and 12 months thereafter. Regular follow-ups with their attending
ENT or maxillofacial specialist were encouraged.Analysis
Response following re-irradiation was analysed using RECIST
criteria [21], acute and late toxicity was evaluated according to
NCI CTCAE v.4.03. Control and survival rates were estimated using
Kaplan–Meier analysis [22] of the Addinsoft XLSTAT Life package.
Locoregional control was calculated from the ﬁrst day of treatment
to occurrence of locoregional failure, progression-free survival was
measured from the ﬁrst day of treatment to occurrence of locore-
gional failure, distant failure, or death.Results
Fifty-two patients with adenoid cystic carcinoma received
re-irradiation using carbon ion therapy for local relapse between
04/2010 and 05/2013.
Median age of these patients was 55 years [35–78 years],
median follow-up to date is 14 months [1–39 months], 13 patients
have deceased thus far. Seven out of 52 patients underwent
surgery for local relapse, 45 patients (86.5%) had macroscopically
visible tumour prior to re-irradiation. Tumour stages were mostly
advanced (T4: 76.9%) while nodal and distant metastases (N+:
Table 2
Acute toxicity at completion of radiotherapy and observed late toxicity to date.
Acute toxicity (CTCAE v. 4.03)
I (pts/%) II (pts/%)
Mucositis 9/17.3 9/11.5
Dermatitis 16/30.8 5/9.6
Xerostomia 25/48.1 3/5.8
Trismus 8/15.4
Hearing impairment 2/3.8
Xerophthalmia 4/7.7
Epiphora 1/1.9
Lymphedema 2/3.8
Conjunctivitis 2/3.8
Dizziness 1/1.9
Headaches 1/1.9
Late toxicity (CTCAE v. 4.03)
Pts %
Xerostomia I 4 7.7
Hyperpigmentation I 2 3.8
Dysphagia I 3 5.8
Dysphagia III 1 1.9
Trismus 6 11.5
CNS necrosis I 8 15.4
CNS necrosis III 2 3.8
Osteoradionecrosis 3 5.8
Tinnitus 1 1.9
Xerophthalmia 2 3.8
Corneal ulcer 1 1.9
Rhinoliquorrhea 1 1.9
Conjunctivitis 1 1.9
Lymphedema 3 5.8
Tissue necrosis 2 3.8
ICA haemorrhage (IV) 2 3.8
Cranial nerve palsy 1 1.9
Dizziness 1 1.9
Chronic otitis 1 1.9
Symptomatic epilepsy I 1 1.9
Dysesthesia 1 1.9
Difﬁculty in concentration 1 1.9
184 Re-irradiation of adenoid cystic carcinoma ACC with carbon ion radiotherapy6 pts/11.5%; M1: 15 pts/28.8%) were less common. Tumours
mostly originated from the paranasal sinuses (36.5%), the base of
skull (21.2%), or the parotid (19.2%). Forty-eight patients (92.3%)
received carbon ions only, 4 patients (7.7%) combined treatment
with IMRT plus carbon ion boost (Table 1: patient characteristics
and radiotherapy).Fig. 1. 3-Field carbon ion IMPT treatment plan of a 50-year old patient with extensive loc
618.2 ml, total dose: 54 GyE (3.0 GyE/fraction).Patients received a median re-irradiation dose of 51 GyE [36–
74 GyE]. Using an alpha/beta of around 2 for adenoid cystic
carcinomas, this corresponds to a median biologically equivalent
dose (BED) of 63 Gy [45–82 Gy]. Target volumes were 93 ml (med-
ian) for carbon ions [range: 9–618 ml] and 334 ml (median) for
IMRT [211–344 ml]. Median prior radiotherapy dose of treated
patients was 66 Gy [20–115 Gy] corresponding to a BED of 66 Gy
[20–133 Gy] as 14 patients had undergone prior carbon ion ther-
apy. Interval between prior radiotherapy and re-irradiation ranged
between 9 and 620 months (median: 61 months) (Table 1: patient
characteristics and radiotherapy).
We observed no grade III acute toxicity; none of the reported
patients had treatment interruptions. There was only II mucositis
(11.5%), dermatitis (9.6%) and xerostomia (5.8%). Eight patients had
trismus, which was a pre-existing condition or due to tumour pro-
cess. Observed acute toxicity quickly resolved, at ﬁrst follow-up
(6–8 weeks post completion of radiotherapy), only one patient still
had grade II xerostomia (1.9%), grade I residual toxicity was 5.8%
(xerostomia, dysphagia) and 3.8% (hyperpigmentation). Trismus
had resolved in 2 patients, leaving 6 patients with residual trismus
(11.5%) (Table 2: toxicity).
Higher-grade late toxicity was rare, however, we observed 8
cases of temporal lobe blood–brain-barrier changes (CNS necrosis
I: 15.4%). Two patients underwent surgery (CNS necrosis III:
3.8%), one developed symptomatic epilepsy (1.9%). Two patients
developed tissue necrosis in the nasopharynx following re-irradia-
tion (3.8%) consequently leading to carotid artery haemorrhage
(CTCIV) (cumulative applied BED: 149 Gy and 182 Gy).
Fortunately, both underwent coiling of the vessel without any con-
secutive symptoms. Osteoradionecrosis was observed in 3 patients
(5.8%) resulting in surgical procedures in one patient (1.9%).
Another patient acquired a chronic corneal ulcer (1.9%) requiring
permanent ophthalmological treatment. In total, 8 patients devel-
oped serious radiation late effects (6.5%) (Table 2: toxicity).
Objective response rates (CR/PR) were 38.5% (CR: 3.8%, PR:
34.6%; SD: 46.2%, dna: 7.7%, unknown: 5.8%) at ﬁrst follow-up
and 53.8% best response (CR: 5.8%, PR: 48.1%; SD: 36.5%, dna:
7.7%, unknown: 1.9%). Fig. 1 shows a 3-ﬁeld carbon ion IMPT plan
(54 GyE in 3 Gy per fraction) of a 50-year old patient with exten-
sive locally recurrent adenoid cystic carcinoma 2 years after initial
diagnosis of his disease. Fig. 2a depicts the initial tumour extensionally recurrent adenoid cystic carcinoma 2 years after initial diagnosis. target volume:
Fig. 2. Corresponding MRI scans of a 50-year old patient with extensive locally recurrent adenoid cystic carcinoma. a: planning MRI (axial/coronal T1 contrast-enhanced, fat-
saturated images); b: follow-up MRI 8 weeks post completion of re-irradiation showing very good PR (axial/coronal T1 contrast-enhanced, fat-saturated images).
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Fig. 3. Local control (LC) and overall survival (OS) following re-irradiation. LC at 1 year: 70.3%, median local control: 19 months OS at 1 year: 81.8%, at 2 years: 63.3%; median
OS: not reached yet.
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186 Re-irradiation of adenoid cystic carcinoma ACC with carbon ion radiotherapyon treatment planning and Fig. 2b a very good partial remission
8 weeks post completion of re-irradiation with carbon ions.
Thirty-three patients relapsed: 18 patients (34.6%) developed
local recurrences: 13 patients within the re-irradiation ﬁeld
(72.2%), 1 at the ﬁeld edge (5.6%), 1 in the dose gradient towards
spared structures (optic chiasm) (5.6%), and 3 patients out of ﬁeld
(16.7%). Fifteen patients developed distant disease progression in
the lung (26.7%), bone (20%), liver, and brain (each 13.3%). Six
patients developed recurrences on both local and distant sites
(18.2%).
Local control at one year is 70.3% (2-year estimate: 47.4%) and
overall survival at one year is 81.8% (2-year estimate: 63.3%)
(Fig. 3). Median local control is 19 months in this cohort. As
expected, higher T-stages show lower local control rates, however,
differences do not reach statistical signiﬁcance in this cohort
(Supplement Fig. 1s). There is also a trend towards improved local
control in adenoid cystic carcinoma with increased re-irradiation
doses (Supplement Fig. 2s).
While T-stage and cumulative life-time dose and short interval
between the two courses of radiotherapy showed a trend towards
less favourable outcome, neither of these factors reached statistical
signiﬁcance (Table 3s).Discussion
Faced with the often long natural history of the disease,
obtaining local control is a very important issue in adenoid cystic
carcinoma of the head and neck even if cure may ultimately not
be possible due to the presence of distant disease. While there is
emerging data on improved local control using re-RT in recurrent
or second primary head and neck cancer, radiation oncologists
have so far eyed re-irradiation with caution for fear of high-grade
late toxicity. In excessively pre-treated patients as in the presented
cohort, there are no valid treatment alternatives once surgical sal-
vage is no longer an option. Chemotherapy was often given in a sit-
uation of local recurrence where neither surgery nor standard
radiotherapy is possible with the aim of stopping/delaying local
progression or ameliorate symptoms of local tumour growth. Com-
bination regimen such as CAP (cyclophosphamide, adriamycin, pla-
tin [1]) can lead to objective tumour response but outcome in
terms of long-term control is dismal. Much effort has gone into
improving toxicity and efﬁcacy with new substances: while toxic-
ity could be reduced with molecular targeted agents such as imati-
nib and sorafenib, these substances may lead to a prolonged
disease stabilization, but reported objective response rates are only
around 10–15% [4,6]. Data on re-irradiation in malignant salivary
gland tumours of the head and neck are scarce, however, there is
emerging evidence on re-irradiation in squamous cell carcinoma
of the head and neck. While toxicity in potentially curative treat-
ment regimen was sometimes unacceptably high, new treatment
techniques such as FSRT/SBRT and IMRT have improved toxicity
proﬁles of re-irradiation dramatically.
Acute toxicity in our cohort was very mild: there was no higher-
grade acute toxicity; toxicity grade II reached a maximum of under
12% (mucositis) supporting our initial ﬁndings [23]. Unfortunately,
available literature mostly concentrates on squamous cell carci-
noma of the head and neck (SCCHN) and re-irradiation with pho-
tons (Supplement Table 1s). More recent publications also
explore the additional use of concomitant chemoradiation in
re-treatment of head and neck cancer (Supplement Table 1s). Com-
parison of our experience with available data is limited and difﬁ-
cult. Lacking data on re-irradiation of ACC with modern
radiotherapy techniques, comparison of the toxicity proﬁles in this
cohort with results of re-irradiation in squamous cell head and
neck cancer in similar anatomical sites and with comparable doselevels is appropriate. Most common treatment sites in our cohort
are paranasal sinus and skull base (57.7%), only few groups report
on these re-treatment sites in substantial proportion
[8,13,16,25,37,40]. Treatment techniques have evolved over the
last two decades, while techniques available to Feehan and Erring-
ton were necessarily based on 2D treatment planning [8,40], Roh,
Lee, and Sulman later reported on results achieved by more
sophisticated treatment techniques such as IMRT and fractionated
stereotactic treatment [13,16,37]. There is currently no data on re-
irradiation with high-precision particle therapy for head and neck
cancer. Information on treated volumes is rarely available, if
reported, median re-treated volumes range between 25 and
50 ml, while our median treatment volume (CTV) is 93 ml with a
range up to more than 600 ml. Treatment-related side effects
may therefore differ substantially between available literature
and data presented here. Despite all the caveats, large treatment
volumes and high re-irradiation and cumulative life-time doses,
we have found no grade III acute toxicity which is in contrast to
available photon series with grade III toxicity rates ranging
between 20% and 46% [16,25,37,40].
Late toxicity has thus far been moderate though our median fol-
low-up with 14 months may yet be short. We did observe 2 cases
(3.8%) of IV ICA haemorrhages following tissue necrosis in the
nasopharynx after cumulative doses of 149 Gy and 182 Gy BED.
Fortunately, both patients underwent successful coiling of the
ICA and recovered well and without sequelae of the occlusion.
One of these patients also developed a swallowing disorder (dys-
phagia III) following soft tissue necrosis and has undergone PEG
placement. Asymptomatic blood–brain barrier changes on MRI
(CNS necrosis I) are not uncommon in high-dose radiotherapy of
reported anatomical sites [41]. Two patients underwent surgery
following diagnosis of these MRI changes, hence these had to be
classiﬁed CNS necrosis grade III. One patient developed symptom-
atic epilepsy and is currently asymptomatic under anticonvulsants.
Carotid blow-out and subsequent fatal haemorrhage was and is
one of the most feared radiation late effects but rarely seen in the
primary situation. In re-irradiation however, many series have
reported the incidence of vascular complications [8,11,12,14–
16,24,25,30,31,36]. In a recent review including data on more than
1500 patients, McDonald et al. found an incidence of 2.6% carotid
artery blow-out with 76% of these complications being fatal [42].
Factors inﬂuencing vascular complication risks include cumulative
dose, fractionation and volume of irradiation. Sparing these struc-
tures in re-irradiation may not be possible though if the tumour
encases or inﬁltrates the vessel [42]. While the rate of vascular
complications in our cohort is higher than the pooled 2.6%, our
treatment volumes and re-irradiation doses are signiﬁcantly above
reported series. Total observed serious late toxicity (6.5%) in com-
parison to other published series is still moderate and less than
reported in other series maybe owing to the sharper dose-gradi-
ents achievable by scanned particle beams. Comparison with avail-
able particle data is hampered by different planning techniques in
the 1980s and today; serious late effects were reported at 6–25% in
these early series [8,9,40].
Tumour response went as high as 53.8% (CR/PR), which com-
pares favourably with reported results including patients with
other histologies (Adenoid cystic carcinoma: 27% of patients)
[39]. Saroja et al. reported complete responses of 83% in patients
with adenocarcinoma, while reported local control at 2 years is
only 44% in this series [9] compared to 47.4% (median local control:
19 months) in our heavily pre-treated patient cohort. Feehan et al.
reported a similar median local control in their series albeit at
higher severe late toxicity [40]. While available re-irradiation ser-
ies have reported local control rates of up to 68% [36] at 2 years for
mainly patients with SCCHN, achieving long-term local control in
adenoid cystic carcinoma has remained a challenge even in the
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the disease. Long-term local control in re-irradiation of adenoid
cystic carcinoma can rarely be achieved in our series despite
aggressive treatments. Based on the neutron experience from the
late 1980s, one of the main parameters for local control in
recurrent ACC is re-irradiation dose [8,9]. Hence, escalation of re-
irradiation dose should have resulted in higher probability of local
control. Despite high re-irradiation doses even to large treatment
volumes, this does not seem to be the case in our cohort as demon-
strated by the cohort’s local control even despite the short follow-
up (Fig. 3, Fig. 2s). However, compared to available chemotherapy
data [45–47], objective treatment response (56.6%) and response
duration (median local control: 19 months) using re-irradiation is
still impressive, especially considering the moderate toxicity pro-
ﬁle and treatment alternatives: with the most effective CAP regime
including cisplatin already given, expected objective response rates
of second or third line treatment will be less than 20% (Supplement
Table 2s). Re-irradiation with carbon ions may therefore be a valu-
able tool in palliative treatment of ACC in order to avoid systemic
treatment as long as possible and prevent local complications due
to aggressive local tumour growth.
Despite high re-irradiation doses, the most common site of
relapse is still within the re-treatment ﬁeld, which is consistent
with observations by other groups [25,29,31,32,34,36–39,48] and
further supports our target volume deﬁnition concept. In contrast
to Duprez, Lee, Haraf, Salama, Hoebers, De Crevoisier we have
found no signiﬁcant correlation of either local control or overall
survival with re-irradiation dose, time interval or target volume
[11,13–15,25,31]. While relapse tumour stage and prior surgery
may show a trend towards inﬂuencing local control and overall
survival, this was reaching nowhere near statistical signiﬁcance.
The same was reported by Sher and colleagues in their retrospec-
tive analysis [36]. In both series this ﬁnding may be attributable
to the retrospective nature of the analysis, low patient number
and therefore lacking statistical power.
Tumour response rates and local control with this new
treatment technique are promising. While long-term local control
continues to be rare, re-irradiation in adenoid cystic carcinoma
remains essentially a palliative treatment. Still, patients may
achieve a median of 19 months local control without severe toxic-
ity and without continuous chemotherapy, therefore re-irradiation
with carbon ions is a valid treatment alternative.
As most local failures following re-irradiation occur within the
re-RT high-dose area, dose escalation may be an option. In view
of observed vascular toxicity, this may be accompanied by increas-
ing severe late effects and should be viewed with caution.Financial support
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